William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
William Blair Reiterates Outperform Rating on ServiceTitan (TTAN): 'we view valuation as attractive'
-
William Blair Reiterates Market Perform Rating on El Pollo Loco (LOCO) following earnings report
-
Oxford Lane Capital Corp. Prices Preferred Stock Offering
-
Leading broker sees 'an attractive risk/reward' in this major AI chip stock
-
William Blair Downgrades PagerDuty (PD) to Market Perform
-
William Blair Reiterates Outperform Rating on VSE Corporation (VSEC): "We view today’s 7% stock drawdown as a buying opportunity"
-
Form N-CEN WILLIAM BLAIR FUNDS For: Dec 31
-
Xenon Pharmaceuticals closes $747.5 million public offering
-
Dianthus Therapeutics completes $719 million public offering
-
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
William Blair Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "entering 2026 with increasing momentum"
-
William Blair Reiterates Market Perform Rating on UiPath Inc. (PATH): "incrementally encouraged"
-
William Blair Reiterates Outperform Rating on Aveanna Healthcare Holdings Inc (AVAH) following acquisition announcement
-
Oxford Lane Capital announces preferred stock offering
-
Oxford Lane Capital Corp. Announces Preferred Stock Offering
-
William Blair: 'We like CRCL for long-term investors'
-
William Blair Reiterates Outperform Rating on AppLovin Corp (APP) following meeting with management
-
William Blair Reiterates Market Perform Rating on Sprinklr Inc (CXM): "a lot to prove on the execution front"
-
William Blair: 'increasing likelihood that Oracle sees significant earnings growth acceleration over the coming years'
-
Dianthus Therapeutics prices $625 million public stock offering
-
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
-
Xenon Pharmaceuticals prices $650 million stock offering at $57 per share
-
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
-
William Blair Reiterates Outperform Rating on Veeva Systems (VEEV) amid Ostro acquisition
-
William Blair Reiterates Outperform Rating on Tenax Therapeutics (TENX): "continue to believe positive top-line results from LEVEL have the potential to drive multifold upside"
-
Medline completes $3.5 billion secondary stock offering
-
Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters’ option to purchase additional shares
-
William Blair Reiterates Outperform Rating on Exagen (XGN) following Q4 results
-
William Blair Reiterates Outperform Rating on LENZ Therapeutics Inc (LENZ): "continue to believe VIZZ holds blockbuster potential"
-
Truelink Capital Closes Oversubscribed Fund II at $2.0 Billion Hard Cap
-
William Blair Reiterates Outperform Rating on Standex International (SXI) following meetings with management
-
William Blair Starts BridgeBio Pharma (BBIO) at Outperform
-
Analysis-Gabon's uncertain push for IMF loan leads regional return to Fund
-
MiniMed closes IPO raising $538 million at $20 per share
-
MiniMed announces closing of Initial Public Offering
-
William Blair Reiterates Outperform Rating on Nayax (NYAX) following earnings
-
William Blair Reiterates Outperform Rating on StoneX Group Inc. (SNEX): "current price looks highly attractive"
-
Dianthus Therapeutics announces $400 million public stock offering
-
Xenon Pharmaceuticals announces $500 million public offering
-
Xenon Pharmaceuticals Announces Proposed Public Offering
-
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
-
William Blair Reiterates Outperform Rating on Kalaris (KLRS): "we see blockbuster potential for TH103 in nAMD"
-
William Blair Reiterates Outperform Rating on Microsoft (MSFT) following product announcements
-
William Blair Reiterates Market Perform Rating on ULTA Beauty (ULTA) ahead of earnings
-
William Blair: 'We expect Microsoft to continue expanding its enterprise wallet share'
-
William Blair Reiterates Outperform Rating on Crawford & Company (CRD-B): "Significant upside is possible"
-
William Blair Reiterates Outperform Rating on Abbvie (ABBV): "competitive across the amylin class"
-
William Blair Downgrades TalkSpace (TALK) to Market Perform
-
William Blair Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE): "we see further room for upside"

